The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s pruritus therapeutic market report forecasts the pruritus therapeutic market size to grow to $17.98 Billion by 2027, with a CAGR (compound annual growth rate) of more than 8%.

Learn More On The Pruritus Therapeutic Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pruritus Therapeutic Market Size Forecast
The global pruritus therapeutic market is expected to grow from $12.09 billion in 2022 to $13.10 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pruritus therapeutic market size is expected to reach $17.98 billion in 2027 at a CAGR of 8.2%.

North America held the largest pruritus therapeutic market share.

Key Pruritus Therapeutic Market Driver ­– Increase In The Incidences Of Skin Disorders
According to World Cancer Research Fund International, a UK-based not-for-profit cancer prevention organisation, there will be 324,635 new Melanoma of skin cancer cases in 2020. Furthermore, according to the American Cancer Society, a non-profit organisation based in the United States, a predicted 97,610 new melanoma cases will be detected in 2023, with around 58,120 in men and 39,490 in women. As a result, the growing prevalence of skin problems will boost the pruritus therapeutic market.

Request for A Sample Of The Global Pruritus Therapeutic Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp

Key Pruritus Therapeutic Market Trend – Product Innovation
Major players in the pruritus therapeutic market are concentrating on the development of novel drugs and therapies for pruritus and related diseases. For example, Maruho Co., Ltd., a Japanese pharmaceutical company, launched the anti-IL-31 receptor, a humanised monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes in August 2022 for the treatment of atopic dermatitis itching. It is the first antibody that blocks IL-31 signalling. IL-31 is a neuroimmune cytokine2 that has been associated to atopic dermatitis development, itch, and skin inflammation3,4. The chemical prevents IL-31 from attaching to its receptor and thereby reduces itch and skin inflammation in atopic dermatitis.

Pruritus Therapeutic Market Segment
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses

Pruritus Therapeutic Market Major Players and Strategies
Major players in the pruritus therapeutic market are Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Galderm, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Abbott Laboratories, Almirall SA, Eisai Co Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., and Lupin.

Albireo Pharma, Inc. was acquired by Ipsen, a biopharmaceutical firm based in France, for an undisclosed sum in March 2023. The acquisition expands Ipsen’s portfolio with promising medicines for rare cholestatic liver illnesses in children and adults, unique pipeline possibilities, and technical and financial strength. Albireo Pharma, Inc. is a biopharmaceutical business established in the United States that is focused on discovering and commercialising innovative bile acid modulators to treat orphan paediatric liver illnesses, gastrointestinal disorders, and pruritus diseases.

The Pruritus Therapeutic Global Market Report 2023 covers regional data on pruritus therapeutic market size, pruritus therapeutic market trends and drivers, opportunities, strategies, and pruritus therapeutic market competitor analysis. The countries covered in the pruritus therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Pruritus therapeutic refers to the treatment of pruritus, which is the unpleasant feeling that causes a person to scratch. It can be caused by a number of circumstances, including exposure to an allergen, dry skin, pregnancy, and the body’s reaction to medication.

View More Reports Related To The Pruritus Therapeutic Market –
Therapeutic Proteins Global Market Report 2023
Therapeutic BCG Vaccines Global Market Report 2023
Therapeutic Nutrients And Minerals Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: